Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction

Summary

The overall primary objective of the PULSE-MI trial is to test the hypothesis that administration of single-dose glucocorticoid pulse therapy in the pre-hospital setting reduces final infarct size in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI)

Timeline

Start

2022-11-14

Primary completion

2024-01-30

Completion

2024-10-17

Publications

• Marquard JM, Lonborg J, Obling LER, Beske RP, Zhou Y, Nepper-Christensen L, Vejlstrup N, Bang LE, Hassager C, Folke F, Andersen LB, Christensen HC, Holmvang L, Pedersen F, Ahlehoff O, Jabbari R, Minkkinen M, Sorensen R, Tilsted HH, Engstrom T. Prehospital pulse-dose glucocorticoid on index of microvascular resistance in patients with ST-segment elevation myocardial infarction: a sub-study of the PULSE-MI trial. J Inflamm (Lond). 2025 Mar 18;22(1):12. doi: 10.1186/s12950-025-00440-2.
• Madsen JM, Engstrom T, Obling LER, Zhou Y, Nepper-Christensen L, Beske RP, Vejlstrup NG, Bang LE, Hassager C, Folke F, Kyhl K, Andersen LB, Christensen HC, Rytoft L, Arslani K, Holmvang L, Pedersen F, Ahlehoff O, Jabbari R, Barfod C, Hougaard M, Minkkinen M, Tilsted HH, Sorensen R, Lonborg JT. Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial. JAMA Cardiol. 2024 Oct 1;9(10):882-891. doi: 10.1001/jamacardio.2024.2298.

Drugs

Indications